Notification and Report Form for Certain Mergers and Acquisitions

| UPE ANNUAL REPORTS AND FINANCIAL INFORMATION | |
|--|--|
| Central Index Key (CIK) Number 0000123456 | |
| Annual/Audit Report Document # or Link | www.pnowellness.com/uploads/annualreport |
| Date of Annual/Audit Report | 12/31/2024 |

16 C.F.R. Part 803 – Appendix

Acquiring Person

Does the person filing notification stipulate that the acquiring person meets the size of person test? See 15 U.S.C. § 18a(a).

| \Box Yes, the lower size of person test | oxtimes Yes, the higher size of person test | □ N/A |
|---|---|-------|
| | | |

| Entity | Minority Holder & D/B/A Name | HQ Address | Percent Held |
|---------------------|------------------------------|------------------------------------|--------------|
| PNO Holding Company | B Fund 1 (dba The Healers) | 555 Everly Way, New York, NY 10001 | 49% |

► Acquiring Person Structure

ENTITIES WITHIN THE ACQUIRING PERSON

| Company or Operating Business d/b/a Name(s): | | | | |
|--|---------|-------|----------|---------|
| Entity Name | City | State | Zip Code | Country |
| PNO Holding Company | Atlanta | GA | 30301 | USA |
| PNO Pharmaceuticals d/b/a PNO Pharma | Atlanta | GA | 30301 | USA |
| NY Acquisition Sub, LLC | Atlanta | GA | 30301 | USA |

ANNUAL REPORTS AND AUDIT REPORTS

| Acquiring Entity or Overlapping Entity | Central Index Key (CIK) Number | Annual/Audit Report File Name or Link | Date of Annual/Audit Report |
|--|-----------------------------------|--|-----------------------------|
| PNO Pharmaceutical Company | 0000654321 | #1 A-1 Annual Financials | 12/31/2024 |

Additional Acquiring Person Information

OWNERSHIP STRUCTURE

| Description of the ownership structure of the acquiring entity | NY Acquisition Sub, LLC is wholly owned by PNO Pharmaceutical Company, which is wholly owned by PNO Holding Company. PNO Wellness plc holds 51% of PNO Holding Company. The remaining 49% is held by B Fund 1. |
|--|--|
| Document # of organizational chart for fund or MLP (or N/A) | N/A |

OFFICERS AND DIRECTORS

| Name of Entity Within Acquiring Person | Name of Officer or Director | Title | List of Other Entities |
|---|-----------------------------|------------|------------------------|
| PNO Holding Company | William Pierce | Vice Chair | B Fund 1 |

TRANSACTION INFORMATION

► Parties

| ACQUIRED UPE(S) |
|---|
| Name: Beta, Inc. |
| Address: 450 Capital Boulevard |
| Address Line 2: |
| City, State, Zip Code: Albany, NY 12201 |
| Country: United States |
| Website: www.betacompany.com |
| |

□ None

🛛 No

| ACQUIRING ENTITY(IES) - (Tab to add additional "Acquiring Entity" entries.) | TARGET – (Tab to add additional "Target" entries.) |
|---|--|
| Name: NY Acquisition Sub, LLC | Name: New York Originators, Inc. |
| Address: 7000 Main Street | Address: 6820 Washington Avenue |
| Address Line 2: | Address Line 2: |
| City, State, Zip Code: Atlanta, GA 30301 | City, State, Zip Code: New York, NY 10001 |
| Country: United States | Country: United States |
| Website: | Website: www.nycoriginators.com |
| | |

Transaction Details

Is this transaction subject to § 801.30?
☐ Yes, Specify Type(s)

TRANSACTION TYPE

Check all that apply:

 \boxtimes Acquisition of voting securities

- $\hfill\square$ Acquisition of non-corporate interests
- □ Acquisition of assets
- □ Merger (see § 801.2)
- □ Consolidation (see § 801.2)

ACQUISITION DETAILS

- □ Formation of a joint venture, other corporation, or unincorporated entity (see §§ 801.40 and 801.50)
- □ Acquisition subject to § 801.31
- \Box Secondary acquisition subject to § 801.4
- □ Acquisition subject to § 801.2(e)
- □ Other, specify ____

| Percentage of voting securities already held % 0 | Percentage of non-corporate interests already held % 0 | | |
|---|--|--|------------------------------|
| Value of voting securities already held (\$MM) \$ 0 | Value of non-corporate interests already held (\$MM) \$ 0 | | |
| Total percentage of voting securities to be held as a result of the acquisition % 100 | Total percentage of non-corporate to be held as a result of the acquisition % 0 | | |
| Total value of voting securities to be held as a result of the acquisition (\$MM) | Total value of non-corporate securities to be held as a result of the acquisition (\$MM) | Total value of assets to be held as a result of the acquisition (\$MM) | Aggregate total value (\$MM) |
| \$ 570.00 | \$ 0 | \$ 0 | \$ 570.00 |

NOTIFICATION THRESHOLD

□ \$50 million (as adjusted) □ \$100 million (as adjusted) □ \$500 million (as adjusted) □ 25% □ N/A

Transaction Description

| BUSINESS OF THE ACQUIRING PERSON | PNO Wellness plc (PNO") is a global manufacturer of pharmaceutical products across general and specialty medicines. Its product profile includes prescription medications in cardiology, endocrinology, hematology, and oncology. |
|----------------------------------|--|
| BUSINESS OF THE TARGET | NY Originators, Inc. ("NYO") is a research and development group founded with the goal of developing new treatments for cancer. |
| NON-REPORTABLE UPE(S) | [none] |
| TRANSACTION DESCRIPTION | Pursuant to a Purchase Agreement dated January 10, 2025, PNO will acquire 100% of the voting securities of NYO from Beta, Inc. ("Beta") for approximately \$570 million. In addition, PNO and Beta will enter into a supply agreement. PNO has created an acquisition vehicle, NY Acquisition Sub, LLC, for the purposes of consummating the transaction. |
| | Consummation of the transaction is scheduled to take place as soon as practicable, and is contingent upon, among other things, satisfactory completion of the conditions outlined in the Purchase Agreement, including the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. |
| | Project New York and Project NYO are code names for the transaction. |

RELATED TRANSACTIONS

| Does the transaction that is the subject of this filing have related filings? | □ Yes | 🛛 No | Unknown |
|--|---------------|----------------|-------------------------|
| If the transaction has related filings, indicate whether the related filing(s) (| choose all th | nat apply): | |
| \Box Is a principal transaction that triggers one or more shareholder | 🗆 Is a jo | int venture | |
| backside transactions | 🗆 Is a co | onsolidation | |
| \Box Is a shareholder backside transaction | 🗆 Is an o | exchange of a | assets |
| □ Has more than one acquiring UPE | 🗆 Has o | ne or more fil | ings in the alternative |
| \Box Has more than one acquired UPE | □ Other | , explain: | |
| \Box Has more than one reportable step | | | |
| | | | |

Party Names or Transaction Numbers for Related Transactions:

► Transactions Subject to International Antitrust Notification

Has (or will) a non-U.S. antitrust or competition authority been (or be) notified of the transaction?

Yes (provide details below)

🗆 No

| Jurisdiction | Date Notified |
|--|--------------------|
| United Kingdom Competition & Markets Authority | Est. February 2025 |

Additional Transaction Information

| TRANSACTION RATIONALE | NYO's unique platform for developing XYZ inhibitors will serve to accelerate PNO's entry into the market – fast-tracking drug development across solid tumors and hematologic malignancies. |
|---|---|
| | Project New York Investment Thesis |
| | Harness Innovation Leverage NYO's unique drug development technology platform Implement NYO's innovative approaches to R&D to drive progress and competitive advantage |
| | Accelerate Commercialization & Expand Product Portfolio - Utilize PNO's government affairs office to facilitate FDA review/approval of target molecules - Leverage PNO's marketing expertise to support new product commercialization |
| | Reduce Costs and Increase Revenues Maximize economies of scale across company verticals (marketing, med affairs, etc.) Develop bundled offerings to realize synergies across the continuum of care |
| DOCUMENT NUMBERS RELATED TO TRANSACTION RATIONALE | Doc #3 (D-1) at 2; Doc #5 (D-3), at 4-5; Doc #6 (D-4) at 2; Doc #7 (D-5) at 6-7; Doc #10 (D-8) at 7-10 |
| DOCUMENT # FOR TRANSACTION DIAGRAM Not applicable, select 801.30 transaction | Doc #2 (C-1) (Transaction Diagram) |

► Joint Ventures

Complete only if acquisition is the formation of a joint venture corporation or unincorporated entity

⊠ Not Applicable

| CONTRIBUTIONS TO BE MADE | |
|---|--|
| DESCRIPTION OF CONSIDERATION | |
| DESCRIPTION OF THE BUSINESS OF THE JOINT VENTURE | |

JOINT VENTURE NAICS CODES

| 6-Digit Code | Code Description |
|--------------|------------------|
| | |

Business Documents

TRANSACTION RELATED DOCUMENTS

| Privileged | Document # | Document Title | Estimated Date | Author/Title |
|------------|------------|--|-----------------------|---|
| | 3 | D-1 PNO Wellness Board Presentation re Project New York | October 9, 2024 | Marta Jones, CEO, PNO Pharma |
| | 4 | D-2 Market Share Analysis | November 6, 2024 | James Jones, EVP of U.S. Strategy, PNO Pharma |
| | 5 | D-3 Management Presentation | September 12, 2024 | Earl James, VP of Corporate Development, PNO Pharma |
| | 6 | D-4 Report on Project New York, presentation to Chloe Lewis | August 15, 2024 | Allen Dexter, Manager, PNO Pharma |
| | 7 | D-5 Analysis of Project New York | August 22, 2024 | Chloe Lewis, Senior Manager, PNO Pharma |
| | 8 | D-6 Confidential Information Memorandum presented to PNO Wellness | July 11, 2024 | M&A Advisory Firm, received by Chloe Lewis, CEO, PNO Pharma |
| | 9 | D-7 Banker's Presentation to PNO Wellness | July 18, 2024 | Coal Hill Bank, received by Chloe Lewis, CEO, PNO Pharma |

| 10 | D-8 Synergy document – Research Department, PNO Pharma | September 12, 2024 | Chet Oswald, VP Research & Development, PNO Pharma |
|----|---|-----------------------|---|
| 11 | D-9 Email exchange | December 2-4, 2024 | Between Marta Jones, CEO, PNO Pharma, and Chloe Lewis, Senior Manager, PNO Pharma |

PLANS AND REPORTS

□ Not Applicable, Select 801.30 Transaction

| Privileged | Document # | Document Title | Estimated Date | Author/Title |
|------------|------------|---------------------------|----------------------|---|
| | 12 | E-1 PNO Quarterly Review | April 15, 2024 | Roger Tyler, VP Marketing, PNO Pharma |
| | 13 | E-2 PNO Quarterly Review | July 15, 2024 | Roger Tyler, VP Marketing, PNO Pharma |
| | 14 | E-3 PNO Quarterly Review | October 14, 2024 | Roger Tyler, VP Marketing, PNO Pharma |
| | 15 | E-4 PNO Quarterly Review | Jan 14, 2025 | Roger Tyler, VP Marketing, PNO Pharma |
| | 16 | E-5 Performance Report | April 15, 2024 | Jane Lannister, VP Sales, PNO Pharma |
| | 17 | E-6 Performance Report | July 15, 2024 | Jane Lannister, VP Sales, PNO Pharma |
| | 18 | E-7 Performance Report | October 14, 2024 | Jane Lannister, VP Sales, PNO Pharma |
| | 19 | E-8 Performance Report | Jan. 14, 2025 | Jane Lannister, VP Sales, PNO Pharma |
| | 20 | E-9 Annual Strategic Plan | March 22, 2024 | Marta Jones, CEO, PNO Pharma |
| | 21 | E-10 Fact Sheet | August 26, 2024 | Roberta Tyrell, Secretary, PNO Pharma |
| | 22 | E-11 Competitor Analysis | March 9, 2024 | Pharma Consultants, LLC |
| | 23 | E-12 R&D Report | February 19, 2024 | Chet Oswald, VP Research & Development, PNO Pharma |

Privilege Log Document # #24 (G-1) (Privilege Log)

► Agreements

TRANSACTION-SPECIFIC AGREEMENTS

□ Not Applicable, 801.30 or Bankruptcy

| Documen | it # | Document Title |
|---------|------|---|
| 25 | F | -1 Purchase Agreement between PNO Wellness plc and Beta, Inc. |
| 26 | F | -2 Draft Covenant Not to Compete and Non-Solicitation Agreement |
| 27 | F | -3 Supply Agreement between PNO Wellness plc and Beta, Inc. |

OTHER AGREEMENTS BETWEEN THE ACQUIRING PERSON AND TARGET

Does the acquiring person have (or within one year of filing, had) any agreements with the target?

 \boxtimes No \Box Yes (provide details below)

| Has Type o | f Agreement | Туре |
|------------|-------------|--|
| □ Yes | ⊠ No | Agreement with non-compete or non-solicitation terms between the acquiring person and target |
| 🗆 Yes | ⊠ No | Lease |
| 🗆 Yes | ⊠ No | Licensing Agreement |
| 🗆 Yes | ⊠ No | Master Service Agreement |
| 🗆 Yes | ⊠ No | Operating Agreement |
| 🗆 Yes | ⊠ No | Supply Agreement |
| □ Yes | 🖾 No | Other |

COMPETITION DESCRIPTIONS

□ Not Applicable, Select 801.30 Transaction

Overlap Description

Briefly describe the acquiring person's principal categories of products or services.

PNO Wellness manufactures drugs in four therapeutic areas:

Cardiac drugs used to treat medical conditions associated with the heart and circulatory system.

Endocrinology medications used to treat disorders of the endocrine system and metabolism.

Hematologic drugs that act on blood and blood-forming organs and are used to treat anemia, bleeding disorders, and blood clots.

Oncology drugs used to treat cancer, including chemotherapy agents, targeted therapies, and immunotherapies.

List and briefly describe current and known planned products or services that compete (or could compete) with the target. (See Instructions)

TYROSINE KINASE INHIBITORS – growth blockers that prevent cancer cells from growing and dividing. Adedog (adalinimib) - ABC inhibitor Lester (leslinimib) - DEF inhibitor Cynthate (cynthinimib) - GHI inhibitor CHEMOTHERAPIES – drugs to target and kill fast-growing cancer cells.

Fancimate (ericatere) - antimitochondrate Cutate (chalrotere) - totallytubularite

IMMUNOTHERAPIES – biological therapies that use the body's immune system to slow, stop and kill cancerous cells. Smartate (isabelamab) - USY-ate Pufuda (pufimab) - PDY-ate Belaball (baelimab) - BLB-ate

Competing Product or Service Details

Product or Service: Sales (\$): 1,100 MM **Oncology Drugs** Categories of Customers: National distributors of oncological pharmaceuticals and related products Top 10 Customers Overall: 1 ABB Health **CDD** Wholesalers 2 3. BCC Cares 4. EFF Supply 5. DEE Distributors 6. XYZ Caredrop 7. JKF Drug Distributors GGH Wholesalers 8. 9. PHC Express 10. LMN Opie Top 10 Customers by Category: [See above]

Supply Relationships Description

RELATED SALES

List and briefly describe the acquiring person's products, services, or assets that are supplied to the target or a business that competes with the target. (See Instructions)

PNO Wellness supplies the following plant-based compounds for use in clinical trials for the development of cancer drugs – babinka altoids, a class of compounds that can inhibit the growth of tumor cells, and pogotoxin analogs, a class of compounds that can block cell division.

□ None

□ None

⊠ None

□ None

Product, Service, or Asset Details

| Product, Service, or Asset: | Sales to Target (\$): 0 |
|-----------------------------|--|
| | Sales to Target's Competitors (\$): 11 MM |
| | Top 10 Customers: |
| | 1. CerDev Medical |
| | Description of Supply or Licensing Agreement: |
| | Supply Agreement between PNO Wellness and CerDev Medical dated March 9, 2024, pursuant to which PNO will supply certain plant-based compounds to CerDev Medical for a term of up to 5 years. |

RELATED PURCHASES

List and briefly describe the products, services, or assets that are purchased by the acquiring person from the target or a business that competes with the target. (See Instructions)

Product, Service, or Asset Details

| Product, Service, or Asset: | Purchases from Target (\$): |
|-----------------------------|---|
| | Purchases from Target's Competitors (\$): |
| | Top 10 Suppliers: |
| | Description of Purchase or Licensing Agreement: |

REVENUE AND OVERLAPS

Does the acquiring person have US revenue? I Yes I No, explain:

► NAICS Codes

| | | | Revenue Range | | | | |
|--------------|---|----------------------------|---------------|---------------------|-------------------|-------|---------|
| 6-Digit Code | Code Description | Operating Business | <\$10MM | \$10MM - \$100MM | \$100MM - \$1B | >\$1B | Overlap |
| 325411 | Medicinal chemicals, uncompounded, manufacturing | PNO Pharmaceutical Company | | | | Х | |

Controlled Entity Geographic Overlaps

STATE LEVEL REPORTING

| NAICS Code | Code Description | Operating Business and D/B/A Name(s) | Person or Associate? | States and Total Number |
|---------------|---|---|-------------------------|----------------------------|
| 325411 | Medicinal chemicals, uncompounded, manufacturing | PNO Pharmaceutical Company (dba PNO Pharma) | Person | National |
| 325411 | Medicinal chemicals, uncompounded, manufacturing | MedDev Inc. | Associate | National |

Date: 2/10/2025

STREET LEVEL REPORTING

| \boxtimes | None |
|-------------|------|
|-------------|------|

| NAICS Code and Description: | | | | | | |
|---|------------------------|-------|--------|-------------|----------------|--|
| Operating Business and D/B/A Name(s) | Person or Associate | State | County | ZIP Code | Street Address | |
| | | | | | | |

Minority-Held Entity Overlaps

 \boxtimes None

| Entity Held and D/B/A Name(s) | Percentage Held | Held By | Person or Associate? | NAICS Code or Industry Overlap with Target |
|-------------------------------|--------------------|---------|----------------------|---|
| | | | | |

Prior Acquisitions

□ None

| Overlapping 6-Digit NAICS Code and Description or | Acquired Entity and | Transaction | Consummation Date |
|---|---|-------------------|-------------------|
| Overlap Product or Service Description | Former HQ Address | Type | |
| 325411 Medicinal chemicals, uncompounded, manufacturing | Nevada Drug Company 400 Lucky Boulevard Las Vegas, NV 89101 | Asset acquisition | June 14, 2022 |

ADDITIONAL INFORMATION

Subsidies from Foreign Entities or Governments of Concern

| SUBSIDIES | \boxtimes None \Box Yes (provide details below) |
|----------------------|---|
| Entity or Government | Description |
| | |
| | |

COUNTERVAILING DUTIES IMPOSED

 \boxtimes None \Box Yes (provide details below)

| Product | Duty Imposed | Jurisdiction |
|---------|--------------|--------------|
| | | |

COUNTERVAILING DUTY INVESTIGATIONS

 \boxtimes None \square Yes (provide details below)

| Product | Jurisdiction Conducting Investigation |
|---------|---------------------------------------|
| | |

Defense or Intelligence Contracts

⊠ None □ Not Applicable, Select 801.30 Transaction

| Entity Within Acquiring Person | Contracting Office | Contracting Office ID | Award ID | NAICS Codes |
|--------------------------------|--------------------|--------------------------|----------|-------------|
| | | | | |

Voluntary Waivers

INTERNATIONAL COMPETITION AUTHORITIES (VOLUNTARY)

The acquiring person agrees to waive the disclosure exemption in the HSR Act for the following competition authorities:

□ None

1. UK Competition & Markets Authority

| Name of Acquiring Person UPE: PNO Wellness plc | Date: 2/10/2025 |
|--|-----------------|
| 3. 4. | 5. 6. |

STATE ATTORNEYS GENERAL (VOLUNTARY)

The acquiring person agrees to waive the disclosure exemption in the HSR Act for the following states:

| State | Permit Disclosure of | | | | |
|-------|---|---------------------------|--|--|--|
| State | Fact of Notification and Waiting Period | Information and Documents | | | |
| | | | | | |

► End Notes

⊠ None

| Number | Note |
|--------|------|
| | |

⊠ None

CERTIFICATION

PENALTIES FOR FALSE STATEMENTS

Federal law provides criminal penalties, including up to twenty years imprisonment, for any person who knowingly alters, destroys, mutilates, conceals, covers up, falsifies, or makes a false entry in any record, document, or tangible object with the intent to impede, obstruct, or influence an ongoing or anticipated federal investigation (see, e.g., Section 1519 of Title 18, United States Code.). It is also a criminal offense to knowingly make a false statement in a federal investigation, obstruct a federal investigation, or conspire to obstruct justice or obstruct or impede the lawful functioning of the government (see, e.g., Sections 371, 1001, and 1505 of Title 18, United States Code).

CERTIFICATION

This NOTIFICATION AND REPORT FORM, together with any and all appendices and attachments thereto, was prepared and assembled under my supervision in accordance with instructions issued by the Commission. Subject to the recognition that, where so indicated, reasonable estimates have been made because books and records do not provide the required data, the information is, to the best of my knowledge, true, correct, and complete in accordance with the statute and rules.

I acknowledge that the Commission or the Assistant Attorney General of the Antitrust Division of the Department of Justice may, prior to the expiration of the initial waiting period pursuant to 15 U.S.C. § 18a, require the submission of additional information or documentary material relevant to the proposed transaction.

| Name (Please Print or Type) | Title |
|-----------------------------|--|
| Marta Jones | Chief Executive Officer PNO Pharmaceuticals |
| Signature | Date |
| Marta Jones | February 8, 2025 |
| | |
| | |

⊠ Sworn under penalty of perjury

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

| Signature | Executed Date |
|-------------|------------------|
| Marta Joues | February 8, 2025 |

□ Notarized

| Subscribed and sworn to before me at the: | | Seal: |
|---|----------|-------|
| City of: | | |
| State of: | | |
| This day of | the year | |
| Signature: | | |
| My commission expires: | | |

| 16 C.F.R. Part 803 – Appendix NOTIFICATION AND REPORT FORM FOR CERTAIN MERGERS AND ACQUISITIONS | Approved by OMB 3084-0005 |
|--|---------------------------|
|--|---------------------------|

THE INFORMATION REQUIRED TO BE SUPPLIED ON THESE ANSWER SHEETS IS SPECIFIED IN THE INSTRUCTIONS

THIS FORM IS REQUIRED BY LAW and must be filed separately by each person that, by reason of a merger, consolidation, or acquisition, is subject to § 7A of the Clayton Act, 15 U.S.C. § 18a, and rules promulgated thereunder (hereinafter referred to as "the rules" or by section number). The rules may be found at 16 CFR Parts 801-03. Failure to file this **Notification and Report Form**, and to observe the required waiting period before consummating the acquisition in accordance with the applicable provisions of 15 U.S.C. § 18a and the rules, subjects any "person," as defined in the rules, or any individuals responsible for noncompliance, to liability for a penalty for each day during which such person is in violation of 15 U.S.C. § 18a. The maximum daily civil penalty amount is listed in 16 C.F.R. § 1.98(a).

Pursuant to the Hart-Scott-Rodino Act, information and documentary material filed in or with this Form is confidential. It is exempt from disclosure under the Freedom of Information Act and may be made public only in an administrative or judicial proceeding, or disclosed to Congress or to a duly authorized committee or subcommittee of Congress.

DISCLOSURE NOTICE - Public reporting burden for this report is estimated at 105 hours per response, including time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this report, including suggestions for reducing this burden to:

Premerger Notification Office Federal Trade Commission 400 7th St. SW Washington, DC 20024

and

Office of Information and Regulatory Affairs Office of Management and Budget Washington, DC 20503

Under the **Paperwork Reduction Act**, as amended, an agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. That number is 3084-0005, which also appears above.

Privacy Act Statement—Section 18a(a) of Title 15 of the U.S. Code authorizes the collection of this information. The primary use of information submitted on this Form is to determine whether the reported merger or acquisition may violate the antitrust laws. Taxpayer information is collected, used, and may be shared with other agencies and contractors for payment processing, debt collection and reporting purposes. Furnishing the information on the Form is voluntary. Consummation of an acquisition required to be reported by the statute cited above without having provided this information may, however, render a person liable to civil penalties up to the amount listed in 16 C.F.R. § 1.98(a) per day. We also may be unable to process the Form unless you provide all of the requested information.

This page may be omitted when submitting the Form.